Article
Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations.
Oncology reports - 1 May 2012
Sato Naoto, Saga Yasushi, Mizukami Hiroaki, Wang Dongdong, Fujiwara Hiroyuki, Takei Yuji, Machida Shizuo, Ozawa Keiya, Suzuki Mitsuaki
Abstract excerpt
The purpose of this study was to explore the possibility of targeted molecular therapy with anti-epidermal growth factor receptor (anti-EGFR) antibody (cetuximab) for the treatment of mucinous ovarian carcinoma. We analyzed EGFR protein expression and KRAS gene mutations in 5 mucinous ovarian carcinoma cell lines RMUG-L, RMUG-S, MN-1, OMC-1 and MCAS and evaluated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.